The United States Food and Drug Administration (FDA) has granted Fast Track Designation to Kintara Therapeutics’ (NASDAQ:KTRA) lead drug candidate VAL-083 for the treatment of patients with newly-diagnosed unmethylated glioblastoma (GBM).
Kintara is currently advancing VAL-083 AGILE clinical study in the phase 2/3 trial to support the development and commercialization of VAL-083 in glioblastoma (GBM).
